Hongli Group Inc. (HLP)
NASDAQ (CM) NASDAQ (CM) Primary 
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP's lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds.
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience
HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus. Key 2026 catalysts include Phase 3 data for HLP003 in major depressive disorder and Phase 2 data for HLP004 in generalized anxiety disorder. HELP's cash burn accelerated to $36.7M in 3Q26, with $195M cash on hand and a $100M ATM facility providing runway through pivotal trial milestones.
